Get the Stockscreener App
19.83
2.37%
0.46
Entrada Therapeutics Inc Stock (TRDA) Latest News
(TRDA) Investment Analysis and Advice - Stock Traders Daily
Connor Clark & Lunn Investment Management Ltd. Increases Holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - MarketBeat
Entrada Therapeutics (TRDA) Is a Great Choice for 'Trend' Investors, Here's Why - Yahoo Finance
Los Angeles Capital Management LLC Makes New $542,000 Investment in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - MarketBeat
Insider Sale at Entrada Therapeutics Inc (TRDA) by President of Research & Development - GuruFocus.com
500: Something went wrong - Investing.com UK
Entrada Therapeutics stock hits 52-week high at $20.28 By Investing.com - Investing.com Canada
Entrada Therapeutics, Inc. (TRDA) Reports Q3 Loss, Tops Revenue Estimates - MSN
HC Wainwright Issues Positive Forecast for Entrada Therapeutics (NASDAQ:TRDA) Stock Price - Defense World
HC Wainwright Analysts Boost Earnings Estimates for TRDA - MarketBeat
Entrada Therapeutics (NASDAQ:TRDA) Stock Price Expected to Rise, Oppenheimer Analyst Says - Defense World
Entrada Therapeutics president sells shares worth $339,280 By Investing.com - Investing.com Australia
Equities Analysts Issue Forecasts for TRDA FY2024 Earnings - MarketBeat
HC Wainwright Has Positive Outlook of TRDA FY2024 Earnings - MarketBeat
Beyond The Numbers: 4 Analysts Discuss Entrada Therapeutics Stock - Benzinga
Oppenheimer Issues Positive Forecast for Entrada Therapeutics (NASDAQ:TRDA) Stock Price - MarketBeat
Entrada Therapeutics stock target increased on positive trial data By Investing.com - Investing.com UK
Entrada Therapeutics (NASDAQ:TRDA) Price Target Raised to $20.00 - MarketBeat
Entrada Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Entrada Therapeutics’ Q3 2024 Financial Highlights - TipRanks
Entrada Therapeutics (NASDAQ:TRDA) Hits New 12-Month HighHere's What Happened - MarketBeat
Entrada Therapeutics stock hits 52-week high at $18.22 By Investing.com - Investing.com UK
Entrada Therapeutics : Corporate Presentation - Marketscreener.com
Entrada Therapeutics Reports Third Quarter 2024 Financial Results - The Manila Times
Here's Why Momentum in Entrada Therapeutics (TRDA) Should Keep going - MSN
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Short Interest Down 19.1% in October - MarketBeat
Short Interest in Entrada Therapeutics, Inc. (NASDAQ:TRDA) Declines By 19.1% - Defense World
Here's What Could Help Entrada Therapeutics (TRDA) Maintain Its Recent Price Strength - MSN
Entrada Therapeutics president sells $10,800 in stock By Investing.com - Investing.com Australia
Natarajan Sethuraman Sells 600 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) Stock - MarketBeat
There Is A Reason Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Price Is Undemanding - Simply Wall St
Oppenheimer Initiates Coverage of Entrada Therapeutics (TRDA) with Outperform Recommendation - MSN
(TRDA) Trading Report - Stock Traders Daily
The Manufacturers Life Insurance Company Purchases 2,146 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
Renaissance Technologies LLC Invests $636,000 in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - MarketBeat
Entrada Therapeutics advances Duchenne treatment trials - Investing.com
Entrada Therapeutics advances Duchenne treatment trials By Investing.com - Investing.com UK
Entrada Therapeutics Presents New Data Supporting its Expanding Duchenne Franchise at the 29th Annual Congress of the World Muscle Society - The Manila Times
HRMY: 3 Small-Cap Biotech Stocks to Buy for Major Upside - StockNews.com
(TRDA) Trading Advice - Stock Traders Daily
Morguard Un (MRT-UN-T) QuotePress Release - The Globe and Mail
Pompe Disease Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, and Market Dynamics, MOA, ROA by DelveInsight | M6P Therapeutics, Entrada Therapeutics, Maze Therapeutics, Astellas - The Globe and Mail
Entrada Therapeutics COO sells shares worth over $13,000 - Investing.com India
Entrada Therapeutics COO sells shares worth over $13,000 By Investing.com - Investing.com Australia
Insider Sale: President & COO Nathan Dowden Sells Shares of Entr - GuruFocus.com
Entrada Therapeutics (NASDAQ:TRDA) Trading 4.8% Higher - MarketBeat
U.S. Gold Corp (USAU-Q) QuotePress Release - The Globe and Mail
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):